Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Petros Pharmaceuticals, Inc.PTPI · Entity 8730 | Director | December 21, 2023 | December 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Petros Pharmaceuticals, Inc.
Report date December 21, 2023 · Filed December 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2033-12-21 | Direct | 40,000 |
Reported balance
After 2023-12-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-21 · Grant · Acquired 40,000 · Balance 40,000 F1: The stock options will vest on April 10, 2024, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options will vest on April 10, 2024, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 21, 2023 Filed Dec 26, 2023 22:05 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001104659-23-129247 · tm2333705-4_4seq1.xml · derivative · entry 1 Bradley Greg · CIK 0001833504 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-12-21 F1 · derivative.exercise_date: The stock options will vest on April 10, 2024, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. through the vesting date. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 22:03 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | Exercise / conversionRestricted Stock Units · Derivative | 6,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-053227 · tm2313909-4_4seq1.xml · derivative · entry 2 Bradley Greg · CIK 0001833504 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · derivative.exercise_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023. F2 · derivative.expiration_date: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023. F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 22:03 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | Exercise / conversionCommon Stock | 6,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-053227 · tm2313909-4_4seq1.xml · nonDerivative · entry 1 Bradley Greg · CIK 0001833504 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · price: On April 7, 2022, the reporting person was granted 6,050 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023. F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 22:00 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantStock Option (Right to Buy) · Derivative | 39,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001104659-23-044711 · tm2312600-2_4seq1.xml · derivative · entry 1 Bradley Greg · CIK 0001833504 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2033-04-10 F1 · derivative.exercise_date: The stock options will vest on the one-year anniversary of the date of grant, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. (the "Company") through the vesting date. Read SEC document |
| January 20, 2023 Filed Jan 25, 2023 21:16 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | Exercise / conversionRestricted Stock Units · Derivative | 2,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-006545 · tm234334-2_4seq1.xml · derivative · entry 2 Bradley Greg · CIK 0001833504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · derivative.exercise_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023. F2 · derivative.expiration_date: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023. F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| January 20, 2023 Filed Jan 25, 2023 21:16 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | Exercise / conversionCommon Stock | 2,264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-006545 · tm234334-2_4seq1.xml · nonDerivative · entry 1 Bradley Greg · CIK 0001833504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · price: On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023. F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 21:00 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantRestricted Stock Units · Derivative | 60,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-044713 · tm2212468d2_4.xml · derivative · entry 1 Bradley Greg · CIK 0001833504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,505 Underlying: Common Stock · 60,505 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F2 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date. F2 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the date of grant, subject to the reporting person's employment on that date. Read SEC document |
| December 22, 2021 Filed Jan 7, 2022 21:44 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantRestricted Stock Units · Derivative | 22,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-002304 · tm222320d2_4.xml · derivative · entry 1 Bradley Greg · CIK 0001833504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,642 Underlying: Common Stock · 22,642 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F2 · derivative.exercise_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date F2 · derivative.expiration_date: The restricted stock units vest on the one year anniversary of the date of grant, subject to the reporting person's employment on that date Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 20:16 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001567619-21-007864 · doc1.xml · derivative · entry 1 Bradley Greg · CIK 0001833504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-08 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 25% on the date of grant, 25% shall vest upon the six-month anniversary of the date of grant and the remainder shall vest in equal installments over the following four fiscal quarters. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.